Taivex is dedicated to the development of novel cancer therapeutics and possesses multiple First-in-Class/Best-in-Class anticancer targeted drugs. Today, the company announced that it will present several latest research advancements at the 2024 American Association for Cancer Research (AACR) Annual Meeting. This includes three small molecule drugs, T-1101, T-1201, and T-1301, all of which have entered clinical trials, with T-1101 and T-1201 expected to submit Phase II clinical trial applications by the end of this year.
T-1101 is a First-in-Class oral capsule formulation with high cytotoxic effects and excellent pharmacokinetics. The drug has shown expected safety and preliminary efficacy outcomes in Phase I clinical trials
T-1201 is an anti-cancer drug of novel small molecule drug conjugate with SN38. It’s administrative via intravenous infusion, and T-1201 would target to phosphatidylserine that express on the outer cell surface of tumor cell, and accumulated T-1201 at tumor site. Later, enzymes (ex: esterase…etc.,) around the tumor sites would break the linkage of T-1201 and releasing cytotoxic drug payload SN38. The drug has shown expected safety and preliminary efficacy outcomes in Phase I clinical trials.
T-1301 is a multi-target tyrosine kinase inhibitor developed as oral capsules. T-1301 exhibited effective growth inhibitions against various types of human cancers, including hematological malignancies (e.g., acute myeloid leukemia (AML)) and various types of solid tumors, including gastrointestinal stromal tumor (GIST), colorectal cancer, etc., and its anti-cancer activity against GIST, including drug-resistant GIST, was superior to the commercial 1st– to 3rd-line anti-cancer therapies, i.e., Glivec/Gleevec, Sutent and Stivarga, The proposed indications for T-1301 are drug-resistant GIST and AML, and may be reassessed based on the latest clinical data.
The abstract information for the three drug projects is as follows:
T-1101:
“Phase 1 dose escalation study of T-1101, a first-in-class oral Hec1/Nek2 inhibitor, in patients with advanced refractory solid tumors”
Session Date and Time: Monday Apr 8, 2024 1:30 PM – 5:00 PM
Location: Poster Section 50
Poster Board Number: 18
Abstract Presentation Number: CT167
T-1201:
“First-in-human phase 1 study of a phosphatidylserine-targeting
small molecule drug conjugate (T-1201) in patients with advanced solid tumors”
Session Date and Time: Monday Apr 8, 2024 1:30 PM – 5:00 PM
Location: Poster Section 50
Poster Board Number: 17
Abstract Presentation Number: CT166
T-1301:
“A phase 1 multi-center, open label, dose escalation study to evaluate the safety, pharmacokinetics (PK) and anti-tumor activity of T-1301, a novel small molecular multi-target kinase inhibitor, in patients with advanced solid tumors”
Session Date and Time: Monday Apr 8, 2024 9:00 AM – 12:30 PM
Location: Poster Section 49
Poster Board Number: 16
Abstract Presentation Number: CT089
